Health Care [ 4/12 ] | Biotechnology [ 18/73 ]
NASDAQ | Common Stock
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
The company was incorporated in 2012 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 22, 25 | -0.81 Decreased by -268.18% | -0.67 Decreased by -20.90% |
| Jul 23, 25 | -0.58 Decreased by -190.00% | -0.44 Decreased by -31.82% |
| Apr 23, 25 | -0.41 Decreased by -57.69% | -0.31 Decreased by -32.26% |
| Feb 5, 25 | -0.32 Decreased by -28.00% | -0.27 Decreased by -18.52% |
| Oct 23, 24 | -0.22 Increased by +4.35% | -0.25 Increased by +12.00% |
| Jul 24, 24 | -0.20 Decreased by -5.26% | -0.27 Increased by +25.93% |
| Apr 24, 24 | -0.26 Decreased by -4.00% | -0.28 Increased by +7.14% |
| Feb 7, 24 | -0.25 Increased by +3.85% | -0.25 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -90.79 M Decreased by -264.02% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -65.56 M Decreased by -194.66% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -45.63 M Decreased by -66.80% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -35.42 M Decreased by -43.94% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -24.94 M Decreased by -10.68% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -22.25 M Decreased by -15.73% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -27.36 M Decreased by -40.06% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 436.00 K Increased by +N/A% | -24.61 M Decreased by -25.80% | Decreased by -5.64 K% Decreased by N/A% |